AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The AstraZeneca and University of Oxford coronavirus vaccine is effective against the Brazil variant, according to a report. But AstraZeneca stock remained muted Friday.

AstraZeneca Covid Vaccine Appears Effective Against Brazil Variant: Report

Europe's COVID-19 vaccine rollout has come under the spotlight again after the Italian government blocked a shipment of Oxford-AstraZeneca plc (NASDAQ: AZN) shots to Australia, reports CNBC. The EU is already struggling to keep up with the pace of inoculations per citizen compared to other advanced economies.

Italy Stops AstraZeneca COVID-19 Vaccine Exports To Australia: CNBC

This is the first use of new rules established by the European Union in January to better control the sourcing of COVID-19 vaccine doses within the bloc.

Italy's ban on AstraZeneca exports to Australia raises fears of vaccine nationalism

San Francisco, California--(Newsfile Corp. - March 4, 2021) - Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action has been filed and certain investors may have valuable claims.Class Period: May 21, 2020 - Nov. 20, 2020Lead Plaintiff Deadline: March 29, 2021Visit: www.hbsslaw.com/investor-fraud/AZNContact An Attorney Now: AZN@hbsslaw.com 844-916-0895AstraZeneca PLC (NASDAQ: AZN) Securities Fraud Class Action:The complaint alleges tha

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts AstraZeneca (AZN) Investors to Securities Fraud Lawsuit Application Deadline, Encourages Investors Who Suffered Losses to Contact the Firm

The European Commission, the institution leading the purchase agreements, has been blamed for not securing enough vaccines.

Italy reportedly blocks shipment of AstraZeneca Covid vaccine destined for Australia

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the “Class Period”).

MARCH 29 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against AstraZeneca PLC – AZN

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.

AZN BREAKING ALERT: ROSEN, A LEADING LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline – AZN

Costco

Johnson & Johnson

Lockheed Martin

PepsiCo

Procter & Gamble

Walmart

Stocks that are worth considering for retirement investors. Low beta stocks with strong fundamentals and a healthy dividend yield.

7 Stocks for Any Retiree to Consider

Moderna

Pharma giant AstraZeneca sold its stake in Moderna for more than $1 billion last year as the upstart biotech firm's COVID-19 vaccine thrust it into the spotlight. AstraZeneca quietly revealed the move in its February annual report, which said the Moderna sale accounted for “a large proportion” of the roughly $1.4 billion it raked in.

AstraZeneca cashed out Moderna stake for $1 billion in 2020

Pfizer

The Pfizer-BioNTech and Oxford-AstraZeneca coronavirus vaccines are both highly effective at preventing over-80s from being admitted to hospital, according to a new study.

Pfizer and AstraZeneca vaccines 'highly effective' at preventing hospital admissions in over-80s

AstraZeneca Just Sold Its Moderna Stock: Should You?

AstraZeneca plc (LON:AZN) said that the US District Court for the Northern District of West Virginia has decided in its favour in litigation against Mylan and Kindeva. The court determined that asserted claims in three of AstraZeneca's patents protecting asthma treatment Symbicort in the US are not invalid.

AstraZeneca says US court rules in its favour for Symbicort litigation

The chief of the country's public health body urged calm and said that no deaths have yet been confirmed to have a direct link to the vaccine.

South Korea Investigating Deaths Of Two Long Term Care Patients Who Received AstraZeneca Vaccine

U.K. scientists are out with a study that could ease concerns about giving older adults AstraZeneca's Covid-19 vaccine.

AstraZeneca's Vaccine Works in Older Adults, UK Says

European officials are coming under increasing pressure to reverse restrictions on who can receive the AstraZeneca Covid vaccine.

Pressured European officials are trying to drum up support for the AstraZeneca Covid vaccine

BioNTech SE

France revises its stance and approves the AstraZeneca–Oxford vaccine for the over-65s.

Single dose of AstraZeneca or Pfizer COVID-19 vaccine cuts hospitalization risk by up to 80%, study shows

A recent study revealed that one dose of either Pfizer Inc (NYSE: PFE)/BioNtech SE (NASDAQ: BNTX) or Oxford-AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine is more than 80% effective in reducing infections and severe illness among those aged over 80, Reuters reports. Public Health England (PHE) found that the Pfizer jab offered between 57% and 61% protection against catching the disease after the first dose.

AstraZeneca, Pfizer/BioNtech Single Shot COVID-19 Jab 80% Effective At Preventing Hospitalizations In Elderly

SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AstraZeneca PLC (NASDAQ: AZN) from May 21, 2020 through November 20, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for AstraZeneca PLC investors under the federal securities laws.

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AstraZeneca PLC– AZN

The cash from the sale of its Moderna holding will help shore up AstraZeneca's finances as it continues to develop its drug pipeline.

AstraZeneca Sold Its Stake in Rival Vaccine Maker Moderna for Over $1 Billion

AstraZeneca plc (LON:AZN) has reportedly cashed in US$1.2bn after selling its 7.7% stake in COVID-19 vaccine maker Moderna, Inc. (NASDAQ:MRNA). The FTSE 100 pharma giant will use the proceeds to shore up its balance sheet as it is about to complete the US$39bn acquisition of US rare diseases specialist Alexion, its biggest yet, The Times reported.

AstraZeneca reportedly cashes in US$1.2bn after selling Moderna, Inc. stake

The sale comes after shares in COVID-19 vaccine maker Moderna soared fivefold in 2020.

AstraZeneca sold its stake in Moderna for more than $1 billion last year

AstraZeneca stock was subject to wild swings in 2020 as the company pushed forward in developing a coronavirus vaccine. Now that the firm has authorization in the U.K., is AZN stock a buy?

South Africa Variant Flummoxes AstraZeneca Vaccine; Is AZN Stock A Buy?

AstraZeneca Plc (NASDAQ: AZN) has announced a deal with Shanghai Junshi Biosciences Co Ltd to market Junshi's cancer drug. Under the agreement, AstraZeneca will be granted the right to market Junshi's anti-PD-1 cancer drug toripalimab for urothelial carcinoma across China and other cancer types in some areas.

AstraZeneca, Junshi Bio In Commercialization Pact For Toripalimab In China

British-based drugmaker AstraZeneca plc (NASDAQ: AZN) has sold its 7.7% stake in Moderna Inc. (NASDAQ: MRNA) for more than $1 billion, the Times reported Sunday. What Happened: AstraZeneca disposed of its stake in Moderna following the U.S. biotechnology company's coronavirus vaccine breakthrough, according to the Times report.

News for AstraZeneca Stock (AZN)